159 related articles for article (PubMed ID: 31658309)
1. Protean cytological, histological and immunohistochemical appearances of medullary thyroid carcinoma: current updates.
Buzdugă CM; Costea CF; Cărăuleanu A; Lozneanu L; Turliuc MD; Cucu AI; Ciocoiu M; Floria M; Tănase DM; Dragomir RA; Haba RM; Dumitrescu AM; Bogdănici CM; Ciobanu Apostol DG
Rom J Morphol Embryol; 2019; 60(2):369-381. PubMed ID: 31658309
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
3. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
5. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
6. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
8. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
9. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
[TBL] [Abstract][Full Text] [Related]
10. Medullary and papillary thyroid carcinomas in a patient with a C634Y mutation in the RET proto-oncogene: A case report.
Ding Y; Feng J; Xu XH; Yao J; Ying RB
Indian J Cancer; 2019; 56(2):173-175. PubMed ID: 31062739
[TBL] [Abstract][Full Text] [Related]
11. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
13. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.
Yeganeh MZ; Sheikholeslami S; Hedayati M
Asian Pac J Cancer Prev; 2015; 16(6):2107-17. PubMed ID: 25824727
[TBL] [Abstract][Full Text] [Related]
14. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
15. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
16. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
17. Update on Targeted Therapy in Medullary Thyroid Cancer.
Okafor C; Hogan J; Raygada M; Thomas BJ; Akshintala S; Glod JW; Del Rivero J
Front Endocrinol (Lausanne); 2021; 12():708949. PubMed ID: 34489865
[TBL] [Abstract][Full Text] [Related]
18. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
19. Surgical management of medullary thyroid carcinoma.
Konstantinidis A; Stang M; Roman SA; Sosa JA
Updates Surg; 2017 Jun; 69(2):151-160. PubMed ID: 28409442
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
